Dividend-paying airline fund U.S. Global Jets ETF (NYSE:JETS) is ready to climb skyward with COVID-19 vaccines showing positive results in late-stage testing, two top investment fund leaders are forecasting. The dividend-paying airline fund appears prepared to rise in the coming months when if the COVID-19 crisis is brought under control once a safe and effective vaccine is available for use by the public. JETS, an exchange-traded fund launched by San Antonio, Texas-based U.S. Global Investors in April 2015, gives investors access to the stocks of air carriers, aircraft manufacturers and related companies worldwide.
The airline fund showed a glimpse of its potential to soar with a gain of 16.11% on Monday, Nov. 9, when news arose on Nov. 9 that Pfizer Inc. (NYSE:PFE) and its German partner BioNTech have produced early data in their stage 3 clinical trial to indicate the COVID-19 vaccine they are testing is more than 90% effective. Positive clinical trials, increased prospects for the COVID-19 vaccine to be widely available next year and the likelihood of Republicans clinging to control of the U.S. Senate will produce the kind of legislative gridlock that will prevent huge tax hikes and reduce the threat of big changes that can roil the markets.
Source: Dividend Investor
Related Articles:
________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.